Bourne Lent Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.75M | Sell |
127,816
-200
| -0.2% | -$11.7K | 2.85% | 10 |
|
|
2025
Q4 | $6.91M | Sell |
128,016
-2,125
| -2% | -$102K | 2.29% | 10 |
|
|
2025
Q3 | $5.87M | Sell |
130,141
-2,500
| -2% | -$117K | 2.09% | 11 |
|
|
2025
Q2 | $6.14M | Sell |
132,641
-2,450
| -2% | -$120K | 2.38% | 11 |
|
|
2025
Q1 | $8.24M | Sell |
135,091
-12,600
| -9% | -$734K | 3.54% | 9 |
|
|
2024
Q4 | $8.35M | Sell |
147,691
-9,501
| -6% | -$531K | 3.18% | 9 |
|
|
2024
Q3 | $8.13M | Sell |
157,192
-1,495
| -0.9% | -$70.1K | 3.09% | 9 |
|
|
2024
Q2 | $6.59M | Sell |
158,687
-3,865
| -2% | -$173K | 2.53% | 11 |
|
|
2024
Q1 | $8.82M | Sell |
162,552
-5,705
| -3% | -$291K | 3.56% | 9 |
|
|
2023
Q4 | $8.63M | Sell |
168,257
-16,734
| -9% | -$878K | 3.5% | 8 |
|
|
2023
Q3 | $10.7M | Sell |
184,991
-21,362
| -10% | -$1.31M | 4.73% | 7 |
|
|
2023
Q2 | $13.2M | Sell |
206,353
-4,700
| -2% | -$315K | 4.6% | 8 |
|
|
2023
Q1 | $14.6M | Sell |
211,053
-600
| -0.3% | -$42.3K | 5.53% | 5 |
|
|
2022
Q4 | $15.2M | Sell |
211,653
-81,875
| -28% | -$6.17M | 6.53% | 5 |
|
|
2022
Q3 | $20.9M | Sell |
293,528
-1,720
| -0.6% | -$125K | 9.07% | 4 |
|
|
2022
Q2 | $22.7M | Sell |
295,248
-1,800
| -0.6% | -$137K | 9.02% | 5 |
|
|
2022
Q1 | $21.7M | Sell |
297,048
-23,450
| -7% | -$1.57M | 6.79% | 5 |
|
|
2021
Q4 | $20M | Sell |
320,498
-44,474
| -12% | -$2.61M | 5.35% | 7 |
|
|
2021
Q3 | $21.6M | Hold |
364,972
| – | – | 6.2% | 5 |
|
|
2021
Q2 | $24.4M | Sell |
364,972
-21,744
| -6% | -$1.42M | 6.85% | 5 |
|
|
2021
Q1 | $24.4M | Sell |
386,716
-5,866
| -1% | -$365K | 7.79% | 4 |
|
|
2020
Q4 | $24.4M | Sell |
392,582
-18,643
| -5% | -$1.15M | 8.02% | 5 |
|
|
2020
Q3 | $24.8M | Sell |
411,225
-6,860
| -2% | -$413K | 9.52% | 4 |
|
|
2020
Q2 | $24.6M | Sell |
418,085
-1,750
| -0.4% | -$105K | 10.61% | 3 |
|
|
2020
Q1 | $23.4M | Sell |
419,835
-2,900
| -0.7% | -$177K | 12.56% | 2 |
|
|
2019
Q4 | $27.1M | Buy |
422,735
+415,315
| +5,597% | +$23.8M | 12.78% | 2 |
|
|
2019
Q3 | $376K | Sell |
7,420
-400
| -5% | -$18.8K | 0.18% | 39 |
|
|
2019
Q2 | $355K | Sell |
7,820
-200
| -2% | -$9.32K | 0.17% | 40 |
|
|
2019
Q1 | $383K | Hold |
8,020
| – | – | 0.19% | 42 |
|
|
2018
Q4 | $417K | Buy |
8,020
+2,300
| +40% | +$124K | 0.25% | 36 |
|
|
2018
Q3 | $355K | Hold |
5,720
| – | – | 0.17% | 46 |
|
|
2018
Q2 | $317K | Sell |
5,720
-1,700
| -23% | -$91.8K | 0.17% | 48 |
|
|
2018
Q1 | $469K | Hold |
7,420
| – | – | 0.25% | 41 |
|
|
2017
Q4 | $455K | Sell |
7,420
-100
| -1% | -$6.25K | 0.25% | 42 |
|
|
2017
Q3 | $479K | Sell |
7,520
-300
| -4% | -$17.5K | 0.25% | 38 |
|
|
2017
Q2 | $436K | Hold |
7,820
| – | – | 0.24% | 40 |
|
|
2017
Q1 | $425K | Hold |
7,820
| – | – | 0.23% | 41 |
|
|
2016
Q4 | $457K | Buy |
7,820
+550
| +8% | +$30.1K | 0.27% | 39 |
|
|
2016
Q3 | $392K | Hold |
7,270
| – | – | 0.29% | 37 |
|
|
2016
Q2 | $535K | Hold |
7,270
| – | – | 0.42% | 32 |
|
|
2016
Q1 | $464K | Hold |
7,270
| – | – | 0.37% | 35 |
|
|
2015
Q4 | $500K | Hold |
7,270
| – | – | 0.38% | 33 |
|
|
2015
Q3 | $430K | Hold |
7,270
| – | – | 0.35% | 34 |
|
|
2015
Q2 | $484K | Sell |
7,270
-1,100
| -13% | -$72.5K | 0.38% | 36 |
|
|
2015
Q1 | $540K | Buy |
+8,370
| New | +$524K | 0.41% | 34 |
|
Other funds holding BMY
VCM
VPM
Bourne Lent Asset Management's BMY Position: Q1 2026 in Review
Bourne Lent Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 0.16% in Q1 2026, selling an estimated $11.7K and leaving 127,816 shares worth $7.75M. The position accounts for 2.85% of the portfolio, ranked #10.
Bourne Lent Asset Management first reported a position in BMY in Q1 2015 and has held it in 45 quarters since. The position peaked at $27.1M in Q4 2019. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Bourne Lent Asset Management held 127,816 shares of Bristol-Myers Squibb worth $7.75M as of Q1 2026.
- Bourne Lent Asset Management sold 200 Bristol-Myers Squibb shares in Q1 2026, an estimated $11.7K.
- Bristol-Myers Squibb made up 2.85% of Bourne Lent Asset Management's portfolio in Q1 2026, its #10 holding.
- Bourne Lent Asset Management first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 45 quarters since.
- Bourne Lent Asset Management's Bristol-Myers Squibb position peaked at $27.1M in Q4 2019.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Bourne Lent Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.